M Eddouks, M Maghrani, L Louedec, M Haloui, J B Michel
The antihypertensive and diuretic effects of the aqueous extract of Retama raetam Forssk. (RR) leaves were studied in both normotensive (WKY) and spontaneously hypertensive rats (SHR). In SHR rats, daily oral administration of RR (20 mg/kg) for three weeks exhibited a significant reduction in blood pressure. The systolic blood pressure decreased significantly from the seventh day (P < 0.01) and persisted through the end of treatment (P < 0.001) in SHR rats. The RR significantly enhanced the diuresis in WKY rats (P < 0.001). Furthermore, oral administration of RR at a dose of 20 mg/kg produced a significant increase on urinary excretion of sodium (P < 0.05), potassium (P < 0.01) and chlorides (P < 0.01) in SHR rats. In WKY rats, RR treatment induced a significant increase on urinary potassium elimination (P < 0.05) without affecting sodium and chloride excretion. Irbesartan (Avapro) 20 mg/kg (body weight), an angiotensin II receptor antagonist, was used as reference drug. No significant changes were noted in heart rate after RR treatment in SHR as well as in WKY rats. Glomerular filtration rate showed a significant increase after RR administration in WKY rats (P < 0.01) and a no significant increase in SHR rats. These results suggest that oral administration of aqueous RR extract exhibited antihypertensive and diuretic effects in SHR rats and diuretic action in WKY rats.
{"title":"Antihypertensive activity of the aqueous extract of Retama raetam Forssk. leaves in spontaneously hypertensive rats.","authors":"M Eddouks, M Maghrani, L Louedec, M Haloui, J B Michel","doi":"10.1300/j157v07n02_05","DOIUrl":"https://doi.org/10.1300/j157v07n02_05","url":null,"abstract":"<p><p>The antihypertensive and diuretic effects of the aqueous extract of Retama raetam Forssk. (RR) leaves were studied in both normotensive (WKY) and spontaneously hypertensive rats (SHR). In SHR rats, daily oral administration of RR (20 mg/kg) for three weeks exhibited a significant reduction in blood pressure. The systolic blood pressure decreased significantly from the seventh day (P < 0.01) and persisted through the end of treatment (P < 0.001) in SHR rats. The RR significantly enhanced the diuresis in WKY rats (P < 0.001). Furthermore, oral administration of RR at a dose of 20 mg/kg produced a significant increase on urinary excretion of sodium (P < 0.05), potassium (P < 0.01) and chlorides (P < 0.01) in SHR rats. In WKY rats, RR treatment induced a significant increase on urinary potassium elimination (P < 0.05) without affecting sodium and chloride excretion. Irbesartan (Avapro) 20 mg/kg (body weight), an angiotensin II receptor antagonist, was used as reference drug. No significant changes were noted in heart rate after RR treatment in SHR as well as in WKY rats. Glomerular filtration rate showed a significant increase after RR administration in WKY rats (P < 0.01) and a no significant increase in SHR rats. These results suggest that oral administration of aqueous RR extract exhibited antihypertensive and diuretic effects in SHR rats and diuretic action in WKY rats.</p>","PeriodicalId":73776,"journal":{"name":"Journal of herbal pharmacotherapy","volume":"7 2","pages":"65-77"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27274025","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The petroleum ether extract from the flower heads of Sphaeranthus indicus Linn. was found to be effective in increasing phagocytic activity, hemagglutination antibody titer and delayed type hypersensitivity when tested in mice. Activity of the petroleum extract was tested at five different dosing levels to establish a dose-response relationship. It was found that 200 mg/kg dose was the optimum dose, and at higher doses the activity was either reduced or showed no further increase. The present study, therefore, reveals that the drug shows good promise as an immunomodulatory agent, which acts by stimulating both humoral and cellular immunity as well as phagocytic function.
{"title":"Immunomodulatory Activity of Petroleum Ether Extract of Flower Heads of Sphaeranthus indicus Linn","authors":"A. Bafna, MPharm S. H. Mishra","doi":"10.1080/J157v07n01_03","DOIUrl":"https://doi.org/10.1080/J157v07n01_03","url":null,"abstract":"The petroleum ether extract from the flower heads of Sphaeranthus indicus Linn. was found to be effective in increasing phagocytic activity, hemagglutination antibody titer and delayed type hypersensitivity when tested in mice. Activity of the petroleum extract was tested at five different dosing levels to establish a dose-response relationship. It was found that 200 mg/kg dose was the optimum dose, and at higher doses the activity was either reduced or showed no further increase. The present study, therefore, reveals that the drug shows good promise as an immunomodulatory agent, which acts by stimulating both humoral and cellular immunity as well as phagocytic function.","PeriodicalId":73776,"journal":{"name":"Journal of herbal pharmacotherapy","volume":"7 1","pages":"25 - 37"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/J157v07n01_03","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60735266","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Nicandro, C. Tsourounis, L. Frassetto, B. Guglielmo
The inhibition or induction of hepatic cytochrome P450 3A4 (CYP3A4) enzyme associated with herbal medicines such as I'm-Yunity™ (Coriolus versicolor) can result in clinically significant herb-drug interactions. The active ingredient of I'm-Yunity™ is believed to be polysaccharopeptide polymer (PSP). Drug interactions between I'm-Yunity™ and other medications or supplements are yet to be investigated. The objective of this single-treatment, one-period, three-phase, open-labeled study was to evaluate the ability of I'm-Yunity™ to inhibit or induce CYP3A4 in 12 healthy adult volunteers (8 women and 4 men) aged between 23 and 54 years through the use of a CYP3A4-specific assay, the erythromycin breath test (EBT). EBT measurements are reported as percentage of 14C-Erythromycin metabolized/hr. Participants were given a 14-day supply of I'm-Yunity™ and instructed to take 1200 mg, three times daily with meals. Comparisons of all subjects' mean CYP3A4 activities were performed with the EBT before and after taking ...
{"title":"In vivo effect of I'm-Yunity on hepatic cytochrome P450 3A4.","authors":"J. Nicandro, C. Tsourounis, L. Frassetto, B. Guglielmo","doi":"10.1300/J157V07N01_04","DOIUrl":"https://doi.org/10.1300/J157V07N01_04","url":null,"abstract":"The inhibition or induction of hepatic cytochrome P450 3A4 (CYP3A4) enzyme associated with herbal medicines such as I'm-Yunity™ (Coriolus versicolor) can result in clinically significant herb-drug interactions. The active ingredient of I'm-Yunity™ is believed to be polysaccharopeptide polymer (PSP). Drug interactions between I'm-Yunity™ and other medications or supplements are yet to be investigated. The objective of this single-treatment, one-period, three-phase, open-labeled study was to evaluate the ability of I'm-Yunity™ to inhibit or induce CYP3A4 in 12 healthy adult volunteers (8 women and 4 men) aged between 23 and 54 years through the use of a CYP3A4-specific assay, the erythromycin breath test (EBT). EBT measurements are reported as percentage of 14C-Erythromycin metabolized/hr. Participants were given a 14-day supply of I'm-Yunity™ and instructed to take 1200 mg, three times daily with meals. Comparisons of all subjects' mean CYP3A4 activities were performed with the EBT before and after taking ...","PeriodicalId":73776,"journal":{"name":"Journal of herbal pharmacotherapy","volume":"7 1","pages":"39-56"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66856953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
J. Nicandro, C. Tsourounis, L. Frassetto, B. Guglielmo
The inhibition or induction of hepatic cytochrome P450 3A4 (CYP3A4) enzyme associated with herbal medicines such as I'm-Yunity™ (Coriolus versicolor) can result in clinically significant herb-drug interactions. The active ingredient of I'm-Yunity™ is believed to be polysaccharopeptide polymer (PSP). Drug interactions between I'm-Yunity™ and other medications or supplements are yet to be investigated. The objective of this single-treatment, one-period, three-phase, open-labeled study was to evaluate the ability of I'm-Yunity™ to inhibit or induce CYP3A4 in 12 healthy adult volunteers (8 women and 4 men) aged between 23 and 54 years through the use of a CYP3A4-specific assay, the erythromycin breath test (EBT). EBT measurements are reported as percentage of 14C-Erythromycin metabolized/hr. Participants were given a 14-day supply of I'm-Yunity™ and instructed to take 1200 mg, three times daily with meals. Comparisons of all subjects' mean CYP3A4 activities were performed with the EBT before and after taking I'm-Yunity™. Results revealed a mean EBT change (SD) from baseline of 0.08% (0.56%) 14C-Erythromycin metabolized/hr, which was not significant (p = 0.63). Therefore, 14 days of exposure to I'm-Yunity™ was not associated with clinically significant CYP3A4 inhibition or induction, suggesting that short-term administration of I'm-Yunity™ with medications primarily metabolized by CYP3A4 is safe and not expected to be associated with significant herb-drug interactions. However, it is still unknown whether interactions exist between I'm-Yunity™ and other medications metabolized by other CYP450 isozymes or enzyme/transporter systems.
{"title":"In vivo Effect of I'm-Yunity™ on Hepatic Cytochrome P450 3A4","authors":"J. Nicandro, C. Tsourounis, L. Frassetto, B. Guglielmo","doi":"10.1080/J157v07n01_04","DOIUrl":"https://doi.org/10.1080/J157v07n01_04","url":null,"abstract":"The inhibition or induction of hepatic cytochrome P450 3A4 (CYP3A4) enzyme associated with herbal medicines such as I'm-Yunity™ (Coriolus versicolor) can result in clinically significant herb-drug interactions. The active ingredient of I'm-Yunity™ is believed to be polysaccharopeptide polymer (PSP). Drug interactions between I'm-Yunity™ and other medications or supplements are yet to be investigated. The objective of this single-treatment, one-period, three-phase, open-labeled study was to evaluate the ability of I'm-Yunity™ to inhibit or induce CYP3A4 in 12 healthy adult volunteers (8 women and 4 men) aged between 23 and 54 years through the use of a CYP3A4-specific assay, the erythromycin breath test (EBT). EBT measurements are reported as percentage of 14C-Erythromycin metabolized/hr. Participants were given a 14-day supply of I'm-Yunity™ and instructed to take 1200 mg, three times daily with meals. Comparisons of all subjects' mean CYP3A4 activities were performed with the EBT before and after taking I'm-Yunity™. Results revealed a mean EBT change (SD) from baseline of 0.08% (0.56%) 14C-Erythromycin metabolized/hr, which was not significant (p = 0.63). Therefore, 14 days of exposure to I'm-Yunity™ was not associated with clinically significant CYP3A4 inhibition or induction, suggesting that short-term administration of I'm-Yunity™ with medications primarily metabolized by CYP3A4 is safe and not expected to be associated with significant herb-drug interactions. However, it is still unknown whether interactions exist between I'm-Yunity™ and other medications metabolized by other CYP450 isozymes or enzyme/transporter systems.","PeriodicalId":73776,"journal":{"name":"Journal of herbal pharmacotherapy","volume":"15 1","pages":"39 - 56"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/J157v07n01_04","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"60735326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Catherine Ulbricht, Chi Dam, Tamara Milkin, Erica Seamon, Wendy Weissner, Jen Woods
This study is an evidence-based systematic review including written and statistical analysis of scientific literature, expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.
{"title":"Banaba (Lagerstroemia speciosa L.): an evidence-based systematic review by the Natural Standard research collaboration.","authors":"Catherine Ulbricht, Chi Dam, Tamara Milkin, Erica Seamon, Wendy Weissner, Jen Woods","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This study is an evidence-based systematic review including written and statistical analysis of scientific literature, expert opinion, folkloric precedent, history, pharmacology, kinetics/dynamics, interactions, adverse effects, toxicology, and dosing.</p>","PeriodicalId":73776,"journal":{"name":"Journal of herbal pharmacotherapy","volume":"7 1","pages":"99-113"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26799375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Diabetes was induced in Groups II, III and IV rats by alloxan monohydrate at the rate of 180 mg/kg body weight. Body weight increased significantly (p < 0.05) after Coldenia procumbens treatment. Treatment with C. procumbens significantly (p < 0.05) reduced the blood glucose level from 394.17 +/- 10.52 (mg/dl) to 152.83 +/- 2.15 (mg/dl) in rats when compared with diabetic control group of rats. Serum triglyceride levels decreased significantly (p < 0.05) from 152.33 +/- 2.75 (mg/dl) to 109.17 +/- 1.74 (mg/dl) in C. procumbens-treated rats. Treatment with C. procumbens significantly (p < 0.05) reduced the serum cholesterol level from 59.83 +/- 1.01 (mg/dl) to 44.33 +/- 1.96 (mg/dl) in rats. The analysis of data indicates that the test drug has good hypoglycemic effect in diabetic rats.
{"title":"Evaluation of antidiabetic activity of Coldenia procumbens in alloxan-induced diabetes in rat.","authors":"Nita Patel, Sunant Raval, Harshad Goriya, Mayur Jhala, Bhola Joshi","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Diabetes was induced in Groups II, III and IV rats by alloxan monohydrate at the rate of 180 mg/kg body weight. Body weight increased significantly (p < 0.05) after Coldenia procumbens treatment. Treatment with C. procumbens significantly (p < 0.05) reduced the blood glucose level from 394.17 +/- 10.52 (mg/dl) to 152.83 +/- 2.15 (mg/dl) in rats when compared with diabetic control group of rats. Serum triglyceride levels decreased significantly (p < 0.05) from 152.33 +/- 2.75 (mg/dl) to 109.17 +/- 1.74 (mg/dl) in C. procumbens-treated rats. Treatment with C. procumbens significantly (p < 0.05) reduced the serum cholesterol level from 59.83 +/- 1.01 (mg/dl) to 44.33 +/- 1.96 (mg/dl) in rats. The analysis of data indicates that the test drug has good hypoglycemic effect in diabetic rats.</p>","PeriodicalId":73776,"journal":{"name":"Journal of herbal pharmacotherapy","volume":"7 1","pages":"13-23"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26799368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Abstracts of the 13th Annual Symposium on Complementary Health Care. December 12-14, 2006. Exeter, United Kingdom.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":73776,"journal":{"name":"Journal of herbal pharmacotherapy","volume":"7 3-4","pages":"1-89"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27851548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BACKGROUND With the removal of stimulant herb ephedra from the market, dietary supplement manufacturers are coming out with many ephedra-free products. Some of these products appear to simply replace ephedra with stimulants by another name. OBJECTIVE To determine the stimulant content of dietary supplements marketed as ephedra-free. DESIGN Survey of the ingredients of dietary supplements that are stated as "ephedra-free" in the label or promotional material. RESULTS Out of 36 products marketed as ephedra-free, 32 (89%) contained a methylxanthine such as caffeine or theobromine, 21 (58%) contained the stimulant synephrine, and 20 (56%) contained both a methylxanthine and synephrine. LIMITATIONS The results of this evaluation pertain only to products discovered through Internet and database searching. CONCLUSIONS Most dietary supplement makers have substituted stimulants by a different name for ephedra in their "ephedra-free" products. Patients need to be advised that ephedra-free products are not necessarily stimulant free and may present a significant risk.
{"title":"Evaluation of the stimulant content of dietary supplements marketed as \"ephedra-free\".","authors":"Philip J. Gregory","doi":"10.1300/j157v07n01_06","DOIUrl":"https://doi.org/10.1300/j157v07n01_06","url":null,"abstract":"BACKGROUND With the removal of stimulant herb ephedra from the market, dietary supplement manufacturers are coming out with many ephedra-free products. Some of these products appear to simply replace ephedra with stimulants by another name. OBJECTIVE To determine the stimulant content of dietary supplements marketed as ephedra-free. DESIGN Survey of the ingredients of dietary supplements that are stated as \"ephedra-free\" in the label or promotional material. RESULTS Out of 36 products marketed as ephedra-free, 32 (89%) contained a methylxanthine such as caffeine or theobromine, 21 (58%) contained the stimulant synephrine, and 20 (56%) contained both a methylxanthine and synephrine. LIMITATIONS The results of this evaluation pertain only to products discovered through Internet and database searching. CONCLUSIONS Most dietary supplement makers have substituted stimulants by a different name for ephedra in their \"ephedra-free\" products. Patients need to be advised that ephedra-free products are not necessarily stimulant free and may present a significant risk.","PeriodicalId":73776,"journal":{"name":"Journal of herbal pharmacotherapy","volume":"7 1 1","pages":"65-72"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66858062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
This study was done to investigate the antimicrobial potentiality of the marine algae collected from different coastal regions of Gujarat and screened for the same. Twenty-six marine algae belonging to Rhodophyceae, Chlorophyceae and Phaeophyceae were screened for their potential antibacterial activity against five clinically important bacterial strains, namely Bacillus cereus, Micrococcus flavus, Citrobacter freundii, Klebsiella pneumoniae and Pseudomonas testosterone. Acetone and methanol were used for extraction; and the extracted yield was more when the solvent used was methanol. The antibacterial activity was done by both Agar disc diffusion method and Agar ditch method. The five bacterial strains showed varied response towards marine algal extracts. The most susceptible bacteria was B. cereus followed by K. pneumoniae and C. freundii while the most resistant bacteria were M. flavus and P. testosteroni. Among the 26 algae screened, E. intestinalis was the most potent alga and thus, this alga was selected for further studies. E. intestinalis was extracted in petroleum ether, 1,4-dioxan, acetone, methanol and DMF, and their antibacterial activity was studied against the above-stated five bacterial strains using agar disc method. Maximum extractive value of E. intestinalis was in methanol (2.05%) and minimum was in acetone (0.38%). The most susceptible bacteria was K. pneumoniae and maximum antibacterial activity was shown by petroleum ether extract and minimum was shown by 1,4-dioxan extract. The most resistant bacteria were M. flavus and C. freundii. The MIC values of E. intestinalis extracts ranged from 2500-9.765 microg/0.5 ml against B. cereus and K. pneumoniae. From these results it is concluded that the acetone extract of E. intestinalis is the most potent extract and can be used as a lead molecule in drug discovery in inhibiting some of the bacterial strains. E. intestinalis can be used as a promising novel marine antimicrobial agent in the coming years.
{"title":"Marine algae: screening for a potent antibacterial agent.","authors":"Ratish Nair, Rajesh Chabhadiya, Sumitra Chanda","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This study was done to investigate the antimicrobial potentiality of the marine algae collected from different coastal regions of Gujarat and screened for the same. Twenty-six marine algae belonging to Rhodophyceae, Chlorophyceae and Phaeophyceae were screened for their potential antibacterial activity against five clinically important bacterial strains, namely Bacillus cereus, Micrococcus flavus, Citrobacter freundii, Klebsiella pneumoniae and Pseudomonas testosterone. Acetone and methanol were used for extraction; and the extracted yield was more when the solvent used was methanol. The antibacterial activity was done by both Agar disc diffusion method and Agar ditch method. The five bacterial strains showed varied response towards marine algal extracts. The most susceptible bacteria was B. cereus followed by K. pneumoniae and C. freundii while the most resistant bacteria were M. flavus and P. testosteroni. Among the 26 algae screened, E. intestinalis was the most potent alga and thus, this alga was selected for further studies. E. intestinalis was extracted in petroleum ether, 1,4-dioxan, acetone, methanol and DMF, and their antibacterial activity was studied against the above-stated five bacterial strains using agar disc method. Maximum extractive value of E. intestinalis was in methanol (2.05%) and minimum was in acetone (0.38%). The most susceptible bacteria was K. pneumoniae and maximum antibacterial activity was shown by petroleum ether extract and minimum was shown by 1,4-dioxan extract. The most resistant bacteria were M. flavus and C. freundii. The MIC values of E. intestinalis extracts ranged from 2500-9.765 microg/0.5 ml against B. cereus and K. pneumoniae. From these results it is concluded that the acetone extract of E. intestinalis is the most potent extract and can be used as a lead molecule in drug discovery in inhibiting some of the bacterial strains. E. intestinalis can be used as a promising novel marine antimicrobial agent in the coming years.</p>","PeriodicalId":73776,"journal":{"name":"Journal of herbal pharmacotherapy","volume":"7 1","pages":"73-86"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"26799373","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gislei Frota Aragão, Marta Cristhiany Cunha Pinheiro, Paulo Nogueira Bandeira, Telma Leda Gomes Lemos, Glauce S de Barros Viana
In the present work, we demonstrated that the mixture of alpha- and beta-amyrin (AMI) from Protium heptaphyllum has antinociceptive activity as was evident from the writhing and formalin tests in mice. AMI (10 and 50 mg/kg, i.p.) inhibited writhing in 73 and 94%, respectively, while preferentially inhibiting the 2nd phase of the response (37 and 51; and 60 and 73% inhibitions of the 1st and 2nd phases, respectively) to the formalin test. Naloxone, an opioid antagonist, did not reverse the antinociceptive effect. AMI (50 mg/kg, i.p.) was also active in the hot plate test, increasing the reaction time to thermal stimulus after 30 and 60 min, by 62 and 71%, respectively. A preventive antiedematogenic effect was observed in mice that had a carrageenan-induced paw edema. Paw volume was significantly and dose-dependently decreased by 39, 42 and 53%, three hours after administration of 10, 25 and 50 mg/kg doses, i.p., respectively. AMI (25 and 50 mg/kg, i.p.) was also able to reverse the edema already induced by carrageenan (curative effect). AMI (10 and 25 mg/kg, i.p.) was equally effective in the dextran- induced paw edema (preventive effect), reducing the paw volume by 50 and 60% at the 2nd hour, and by 63 and 73% at the third hour post-dose. AMI (50 mg/kg, i.p.) reverted the edema already formed after the dextran injection (curative effect). In conclusion, AMI demonstrated peripheral and central analgesic effects independent of the opioid system, and also showed a potent anti-inflammatory activity. The antiinflammatory activity was potentiated by both indomethacin and thalidomide, suggesting a potential involvement of prostaglandins and TNFalpha inhibitions.
{"title":"Analgesic and anti-inflammatory activities of the isomeric mixture of alpha- and beta-amyrin from Protium heptaphyllum (Aubl.) march.","authors":"Gislei Frota Aragão, Marta Cristhiany Cunha Pinheiro, Paulo Nogueira Bandeira, Telma Leda Gomes Lemos, Glauce S de Barros Viana","doi":"10.1300/j157v07n02_03","DOIUrl":"https://doi.org/10.1300/j157v07n02_03","url":null,"abstract":"<p><p>In the present work, we demonstrated that the mixture of alpha- and beta-amyrin (AMI) from Protium heptaphyllum has antinociceptive activity as was evident from the writhing and formalin tests in mice. AMI (10 and 50 mg/kg, i.p.) inhibited writhing in 73 and 94%, respectively, while preferentially inhibiting the 2nd phase of the response (37 and 51; and 60 and 73% inhibitions of the 1st and 2nd phases, respectively) to the formalin test. Naloxone, an opioid antagonist, did not reverse the antinociceptive effect. AMI (50 mg/kg, i.p.) was also active in the hot plate test, increasing the reaction time to thermal stimulus after 30 and 60 min, by 62 and 71%, respectively. A preventive antiedematogenic effect was observed in mice that had a carrageenan-induced paw edema. Paw volume was significantly and dose-dependently decreased by 39, 42 and 53%, three hours after administration of 10, 25 and 50 mg/kg doses, i.p., respectively. AMI (25 and 50 mg/kg, i.p.) was also able to reverse the edema already induced by carrageenan (curative effect). AMI (10 and 25 mg/kg, i.p.) was equally effective in the dextran- induced paw edema (preventive effect), reducing the paw volume by 50 and 60% at the 2nd hour, and by 63 and 73% at the third hour post-dose. AMI (50 mg/kg, i.p.) reverted the edema already formed after the dextran injection (curative effect). In conclusion, AMI demonstrated peripheral and central analgesic effects independent of the opioid system, and also showed a potent anti-inflammatory activity. The antiinflammatory activity was potentiated by both indomethacin and thalidomide, suggesting a potential involvement of prostaglandins and TNFalpha inhibitions.</p>","PeriodicalId":73776,"journal":{"name":"Journal of herbal pharmacotherapy","volume":"7 2","pages":"31-47"},"PeriodicalIF":0.0,"publicationDate":"2007-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"27274023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}